Expression of transforming growth factor-beta 3 by embryonal carcinoma cells, parietal endoderm-like cells and early mouse embryos

In Vitro Cell Dev Biol. 1990 Dec;26(12):1181-5. doi: 10.1007/BF02623696.

Abstract

Utilizing the technique of reverse transcription-polymerase chain reaction (RT-PCR), we have examined the expression of transforming growth factor-beta 3 (TGF-beta 3) by embryonal carcinoma (EC) cells, EC-derived differentiated cells and early mammalian embryos. Using a TGF-beta bioassay, we determined that PYS-2 cells express considerable TGF-beta activity that cannot be completely neutralized by antibodies specific for TGF-beta 1 and TGF-beta 2. We also have determined that PYS-2 cells, as well as F9 EC cells and their differentiated cells, express transcripts for TGF-beta 3. In addition, we have determined that blastocysts, cultured for three days in serum-containing medium, express TGF-beta 3 transcripts. Thus, our data suggest that expression of TGF-beta 3 is initiated during early stages of mammalian development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Blastocyst / metabolism
  • Bucladesine / pharmacology
  • Cell Differentiation / drug effects
  • Cell Line
  • Embryo, Mammalian*
  • Embryonal Carcinoma Stem Cells
  • Endoderm / metabolism*
  • Gene Expression*
  • Mice
  • Morula / metabolism
  • Neoplastic Stem Cells / metabolism*
  • Polymerase Chain Reaction
  • Transcription, Genetic
  • Transforming Growth Factor beta / biosynthesis*
  • Transforming Growth Factor beta / genetics
  • Tretinoin / pharmacology

Substances

  • Transforming Growth Factor beta
  • Tretinoin
  • Bucladesine